Early mitoxantrone-induced cardiotoxicity detected in secondary progressive multiple sclerosis

Clinical Medicine Insights: Therapeutics

Volumn 3, Issue , 2011, Pages 449-458

  Namaka, M P ^a   Turcotte, D A ^a   Klowak, M ^a   Leong, C M ^a   Grossberndt, A ^a   le Dorze, J A ^a   Prout, M E ^a   Andresen, S ^a   Vuong, L ^a   Melanson, M J ^b   Frost, E E ^a   Doupe, M ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cardiotoxicity; Expanded disability status score; Left ventricular ejection fraction; Mitoxantrone; MUGA; Secondary progressive multiple sclerosis

Indexed keywords

MITOXANTRONE;

ADULT; ARTICLE; CANADA; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HUMAN; LUNG EDEMA; MALE; MULTIPLE GATED ACQUISITION SCAN; MULTIPLE SCLEROSIS; OFF LABEL DRUG USE; OPEN STUDY; QUALITY OF LIFE; RADIOLOGICAL PARAMETERS; SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS; SIDE EFFECT; TACHYCARDIA; URINARY TRACT INFECTION;

EID: 80555134775     PISSN: 1179559X     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/CMT.S7586     Document Type: Article

References (74)

1. Abdi S, Lee D, Chung J. The anti-allodynic effects of amitriptyline, gaba-pentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg. 1998;87:1360-6.
2. Sorensen PS. Multiple sclerosis: pathophysiology revisited. Lancet Neurol. 2005;4(1):9-10.
3. Namaka M, Leong C, Grossberndt A, et al. A treatment algorithm for neuropathic pain: an update. Consult Pharm. 2009;24(12):885-902.
4. Namaka M, Leong C, Prout M, et al. Emerging Therapies for the Management of Multiple Sclerosis. Clinical Medicine Insights: Therapeutics. 2010; 2010(1977):307.
5. Namaka M, Turcotte D, Leong C, Grossberndt A, and Klassen D. Multiple sclerosis: etiology and treatment strategies. Consult Pharm. 2008;23(11):886-96.
6. Melanson M, Grossberndt A, Klowak M, et al. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon Beta. Int J Neurosci. 2010;120(10):631-40.
7. Basso O, Campi R, Frydenber M, et al. Multiple sclerosis in women having children by multiple partners. A population-based study in Denmark. Mult Scler. 2004;10:621-5.
8. Namaka M, Kapoor S, Simms L, et al. Molecular Mimicry and Multiple Sclerosis. J. Neurological Research. 2010.
9. Compston A. The genetic epidemiology of multiple sclerosis. Philos Trans R Soc Lond B Biol Sci. 1999;354:1623-34.
10. Czlonkowska, Gromadzka, ACG, Kurkowska-Jastrzebska I. Estrogen and cytokines production-the possible cause of gender differences in neurological diseases. Curr Pharm Des. 2005;11:1017-30.
11. Boden Aetrcwr, Thompson E. A possible link between multiple sclerosis and creutzfeldt-jakob disease based on clinical, genetic, pathological and immunological evidence involving acinetobacter bacteria. Med Hypotheses. 2005;64:487-94.
12. Kalman B, Leist TP. Familial multiple sclerosis and other inherited disorders of the white matter. Neurologist. 2004;10(4):201-15.
13. Koch S, Goedde R, Nigmatova V, et al. Association of multiple sclerosis with ILT6 defciency. Genes Immun. 2005;6(5):445-7.
14. Ransohoff RM. Immunologic correlates of MS pathologic subtypes. Mult Scler. 2005;11(1):101-2.
15. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci. 1993;20(1):17-29.
16. Wynn DR, Rodriguez M, O'Fallon WM, Kurland LT. Update on the epidemiology of multiple sclerosis. Mayo Clin Proc. 1989;64(7):808-17.
17. Namaka M, Leong C, Prout M, et al. Emerging therapies for the management of multiple sclerosis. Clinical Medicine Insights: Therapeutics. 2010; 2:307-19.
18. Frost EE, Pillai PP, Begum F, et al. The cellular pathology of multiple sclerosis and prospects for disease modifying therapies. Current Opinion in Investigational Drugs. 2010.
19. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol. 1994; 36 Suppl:S6-11.
20. Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63 (12 Suppl 6):S15-8.
21. Gonsette RE. Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler. 1996;1(6):329-32.
22. Alderton P, Gross J, Green M. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 1992;52(1):194-201.
23. Mesaros S, Stojsavljevic N, Dujmovic I, Mandic E, Drulovic J. Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis. Srp Arh Celok Lek. 2004;132(7-8):209-13.
24. Martinelli V, Radaelli M, Straff L, Rodegher M, Comi G. Mitoxantrone: benefts and risks in multiple sclerosis patients. Neurol Sci. 2009; 30 Suppl 2:S167-70.
25. Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006;28(4):461-74.
26. Cross, Jaa, Abbey, Bcbsbse, Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler. 2003; 9:59-62.
27. Feuillet L, Guedj E, Eusebio A, et al. Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis. Rev Neurol (Paris). 2003;159(12): 1169-72.
28. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology. 2002;59(6):909-13.
29. Pericot I, Montalban X. Mitoxantrone. Neurologia. 2003;18(6):318-23.
30. Noseworthy J, Miller D, Compston A. Disease-modifying treatments in multiple sclerosis, in Mcalpine's Multiple Sclerosis. 2006, Churchill Livingstone: New York: 751-3.
31. Hamzehloo A, Etemadifar M, Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. Arch Iran Med. 2006;9(2):111-4.
32. Cohen, Mikol D. Mitoxantrone treatment of multiple sclerosis: Safety considerations. Neurology. 2004;63:S28-32.
33. Goffette S, van Pesch V, Vanoverschelde JL, Morandini E, Sindic CJ. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J Neurol. 2005;252(10):1217-22.
34. Paul F, Dorr J, Wurfel J, Vogel HP, Zipp F. Early mitoxantrone-induced car-diotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2007;78(2):198-200.
35. Perini P, Calabrese M, Tiberio M, Battistin FRL, Gallo P. Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: A comparative study. J Neurol. 2006;253:1034-40.
36. Drouin E, Nataf S, Lande G, Louboutin J. Abnormalities of cardiac repolarization in multiple sclerosis: Relationship with a model of allergic encephalomyelitis in rat. Muscle Nerve. 1998;21:940-2.
37. Akgul F, McLek I, Duman T, et al. Subclinical left ventricular dysfunction in multiple sclerosis. Acta Neurol Scand. 2006;114:114-8.
38. Ziaber J, Chmielewski H, Dryjanski T, Goch JH. Evaluation of myocardial muscle functional parameters in patients with multiple sclerosis. Acta Neurol Scand. 1997;95(6):335-7.
39. Olindo S, Guillon B, Helias J, et al. Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur J Neurol. 2002;9(3):287-91.
40. Pattoneri P, Sozzi F, Pela G, et al. Assessment of mitoxantrone-induced car-diotoxicity in patients with multiple sclerosis: a tissue Doppler echocardio-graphic analysis. Echocardiography. 2009;26(4):397-402.
41. Senaratne MP, Carroll D, Warren KG, Kappagoda T. Evidence for cardiovascular autonomic nerve dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1984;47(9):947-52.
42. Thomaides TN, Zoukos Y, Chaudhuri KR, Mathias CJ. Physiological assessment of aspects of autonomic function in patients with secondary progressive multiple sclerosis. J Neurol. 1993;240(3):139-43.
43. Linden D, Diehl RR, Berlit P. Subclinical autonomic disturbances in multiple sclerosis. J Neurol. 1995;242(6):374-8.
44. Nordenbo AM, Boesen F, Andersen EB. Cardiovascular autonomic function in multiple sclerosis. J Auton Nerv Syst. 1989;26(1):77-84.
45. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105-13.
46. Meyer C, Ansorge N, Siglienti I, et al. Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia. Nervenarzt. 2010;81(12):1483-9.
47. Bainbridge JL, Corboy JR. Multiple Sclerosis (Chapter). In: DiPiro JT, Talbert RL, Yee GC, Matzke, GR, Wells, BG, Posey, LM. Pharmacotherapy: A Pathophysiologic Approach (7th edition). 2008, McGraw-Hill: New York. http://www.accesspharmacy.com.proxy1.lib.umanitoba.ca/content.aspx?aID=3203058.
48. Martinelli V, Radaelli M, Straff L, Rodegher M, Comi G. Mitoxantrone: benefts and risks in multiple sclerosis patients. Neurol Sci. 2009; 30 Suppl 2:S167-70.
49. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 1998, Lawrence Erlbaum Associates: New Jersey.
50. Rice GP. Treatment of secondary progressive multiple sclerosis: current recommendations and future prospects. Bio Drugs. 1999;12(4):267-77.
51. Fazekas F, Sorensen PS, Filippi M, et al. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler. 2005;11(4):433-40.
52. Humle Jorgensen S, Sorensen PS. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J Neurol Sci. 2005;233(1-2):61-5.
53. Stangel M, Gold R. Intravenous Immunoglobulins in MS. Int MSJ. 2005;12(1):5-10, 4.
54. Steck AJ. Use of intravenous immunoglobulin in neurological disorders. Rev Med Suisse. 2005;1(17):1167-70.
55. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2): 169-78.
56. Benesova Y, Stourac P, Beranek M, Kadanka Z. Mitoxantrone therapy in rapidly worsening multiple sclerosis. Bratisl Lek Listy. 2005;106:141-3.
57. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs. 2005;19(5):369-76.
58. Montu MB, Arruda WO, de Oliveira Mde S, Ramina R. Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients. Arq Neuropsiquiatr. 2005;63(2A):225-7.
59. Neuhaus O, Kieseier BC, Hartung HP. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther. 2006;109(1-2):198-209.
60. Singhal BS, Geeta S, Hundalani SG, Menon S. Effcacy and safety of mitox-antrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting. Neurol India. 2009;57(4):418-23.
61. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018-25.
62. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62(2):112-8.
63. Gonsette R, Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: A pilot study for 2 years in 22 patients. Neurol. 1990;40:261.
64. Kappos L, Kunstler RGE. Mitoxantrone (MX) in the treatment of rapidly progressing MS: A pilot study with serial gadolinium (gd)-enhanced MRI. Neurol. 1990;40:261.
65. Milleforini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol. 1997;244(3):153-9.
66. Wang GX, Zhou XB, Eschenhagen T, Korth M. Effects of mitoxantrone on action potential and membrane currents in isolated cardiac myocytes. Br J Pharmacol. 1999;127(2):321-30.
67. Shipp NG, Dorr RT, Alberts DS, Dawson BV, Hendrix M. Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Res. 1993;53(3): 550-6.
68. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11(3):306-9.
69. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci. 1992;242(2-3):96-102.
70. Investigators TS. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302.
71. Rashid H, Exner DV, Mirsky I, et al. Comparison of echocardiography and radionuclide angiography as predictors of mortality in patients with left ventricular dysfunction (studies of left ventricular dysfunction). Am J Cardiol. 1999;84(3):299-303.
72. Thompson KL, Rosenzweig BA, Zhang J, et al. Early alterations in heart gene expression profles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol. 2009;66(2):303-14.
73. Tonomura Y, Mori Y, Torii M, Uehara T. Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats. Toxicology. 2009;266(1-3):48-54.
74. Peak S, Tsao-Wei D, Chamberlain M. Mitoxantrone in secondary progressive multiple sclerosis: a review of toxicity in 41 patients. Therapy. 2007;4: 55-58.